-
2024 FDA Issued CRLs
FDA
The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
-
Next Domestic Big Drug
Astellas
Astellas has secured FDA approval for Zolbetuximab, the first Claudin18.2-targeted antibody for advanced HER2-negative gastric cancer. This breakthrough opens a new market, addressing a critical need in cancer treatment and forecasting substantial sales growth in the coming years.
克拉玛依市|
都江堰市|
睢宁县|
莲花县|
高雄县|
张家界市|
巴林左旗|
通江县|
宝应县|
汶川县|
沈阳市|
老河口市|
顺平县|
原阳县|
台东县|
厦门市|
永仁县|
大港区|
镇江市|
淅川县|
洛扎县|
东丽区|
和林格尔县|
都江堰市|
富蕴县|
遵化市|
临江市|
安溪县|
内江市|
旺苍县|
陆良县|
石屏县|
石景山区|
勃利县|
沂水县|
射洪县|
平安县|
凉城县|
苏州市|
芜湖市|
鱼台县|